By Lina carolina 
Scientists and medics have developed an ultra-rapid method of genetically diagnosing brain tumours that will cut the time it takes to classify them from six to eight weeks, to as little as two hours, which could improve care for thousands of patients each year in the UK. This groundbreaking advancement, detailed in a new study published in Neuro-Oncology, represents a significant leap forward in the fight against brain cancers, promising to alleviate immense patient anxiety and expedite crucial treatment decisions.
The collaborative effort, spearheaded by researchers at the University of Nottingham and clinicians at Nottingham University Hospitals NHS Trust (NUH), has successfully trialled a novel approach that delivers near-instantaneous diagnostic results. This new technology has the potential to fundamentally alter the pathway for brain tumour patients, moving from a weeks-long waiting game to a matter of hours.
The Need for Speed: A Critical Bottleneck in Brain Tumour Care
The urgency of diagnosing brain tumours cannot be overstated. In the UK, an alarming 34 people are diagnosed with some form of brain tumour every day, equating to over 12,000 cases annually. For the most aggressive forms of brain cancer, the average survival rate can be less than a year, underscoring the critical importance of swift and accurate diagnosis to initiate timely and effective treatment.
Traditionally, the diagnostic process for brain tumours has been a protracted and arduous journey. Following surgical removal of a tumour, tissue samples are sent to centralised laboratories for complex genetic testing. This process, which involves intricate DNA analysis to identify specific genetic abnormalities that define tumour type and guide treatment, can take a staggering six to eight weeks, and often longer, to yield complete results. This extended waiting period is not merely inconvenient; it is a source of profound psychological distress for patients and their families, adding layers of anxiety to an already devastating diagnosis. Furthermore, the delay in obtaining definitive classification can postpone the commencement of vital treatments such as radiotherapy and chemotherapy, potentially diminishing their efficacy and impacting long-term outcomes.
A Paradigm Shift: The Nottingham Innovation
The University of Nottingham and NUH team’s innovation directly addresses this critical bottleneck. Their ultra-rapid genetic diagnostic method has been designed to eliminate the agonizing wait that has long plagued brain tumour patients. The technology is so advanced that it can provide diagnostic results within a mere two hours of a surgical procedure, with detailed tumour classifications available in minutes following genetic sequencing.
Crucially, the platform’s capability for continuous sequencing allows for a fully integrated diagnosis within 24 hours, offering a comprehensive understanding of the tumour’s genetic makeup. This speed and precision open up unprecedented possibilities, including the potential to inform surgical decision-making in real-time during an operation.
Intraoperative Success: A Testament to the New Technology
During the development and validation phase, the NUH clinical team successfully employed the new approach in 50 brain tumour surgeries. The results have been nothing short of remarkable, achieving a 100% success rate in delivering rapid, intraoperative diagnoses. This unprecedented level of efficiency and accuracy marks a significant milestone in neuro-oncology.
Dr. Stuart Smith, a Neurosurgeon from the School of Medicine at the University and within NUH, highlighted the transformative potential of this breakthrough. "Traditionally, the process of diagnosing brain tumours has been slow and expensive," he stated. "Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision-making, in as little as two hours. Patients find waiting many weeks for results extremely difficult, and this adds to the anxiety and worry at what is already a very difficult time."
Dr. Smith further elaborated on the immediate impact during surgical procedures. "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy," he explained. This intraoperative insight could allow surgeons to make more informed decisions about the extent of tumour resection, potentially improving surgical outcomes and minimizing the risk of recurrence.
The Science Behind the Speed: Nanopore Sequencing and ROBIN
The technological foundation of this rapid diagnostic method lies in Professor Matt Loose’s pioneering work in DNA sequencing, utilizing Oxford Nanopore Technologies’ portable sequencing devices. Professor Loose, a biologist from the School of Life Sciences at the University of Nottingham, developed a method to sequence specific segments of human DNA with exceptional depth and speed. This approach allows for the targeted examination of crucial genomic regions, significantly accelerating the diagnostic process.
Traditionally, sequencing an entire human genome was a complex and time-consuming undertaking, often involving multiple laboratories and months of work. Professor Loose’s innovation enables researchers to select and sequence only the most relevant parts of the human genome, directly addressing the specific questions needed for tumour classification and treatment planning.
The system now employs ROBIN, a sophisticated software tool designed to work with P2 PromethION nanopore sequencers. ROBIN sequences DNA by detecting minute changes in electrical current as individual DNA molecules pass through a tiny pore in a membrane. This method allows for the rapid and detailed analysis of genetic material.
"When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient," Professor Loose explained. "This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how it can be treated. Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
The critical genetic marker for tumour classification in this context is methylation, a process that alters gene expression without changing the underlying DNA sequence. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need. Methylation is the one we are most interested in early on in this instance because that defines the tumour type," Professor Loose added.
The workflow involves obtaining a surgical sample, extracting the DNA in the pathology lab, and then sending it to the research team for rapid sequencing. This streamlined process ensures that the genetic information is analysed swiftly and efficiently.
Expert Endorsement: A Game Changer for Neuropathology
The implications of this rapid diagnostic tool have been met with considerable enthusiasm from the medical community. Dr. Simon Paine, a Consultant Neuropathologist at NUH, described the new method as a "game changer" and "truly revolutionary." He emphasized not only the increased speed of results but also the "incredible degree of accuracy" offered by the technology.
Beyond Speed: Cost-Effectiveness and Equity of Access
Beyond its remarkable speed and accuracy, the new diagnostic method also boasts significant cost advantages. Professor Loose revealed that the estimated cost per person is around £450, with the potential for further reductions when scaled up. This cost-effectiveness stems from several factors, most notably the ability of the single, comprehensive test to eliminate the need for four to five separate, traditional tests. This consolidation of diagnostic procedures not only reduces expenses but also significantly streamlines the overall process, ensuring that vital results are delivered to patients precisely when they are needed most.
The Brain Tumour Charity, a leading advocate for brain tumour patients and research, has lauded the potential of this innovation to improve patient care and drive research forward. Dr. Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, stated, "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients, ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis."
Dr. Newman further highlighted the broader implications for equitable access to advanced diagnostics. "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis," he remarked. The charity is actively supporting the BRAIN MATRIX Trial, which is exploring how this cutting-edge technology can be leveraged to match patients with personalized clinical trials across the UK, further accelerating the development of tailored treatment strategies.
The Road Ahead: National Rollout and Future Prospects
The success of the trials at Nottingham has paved the way for wider implementation. The team is now actively working towards rolling out this revolutionary testing across NHS Trusts throughout the UK. This national adoption promises to bring the benefits of rapid, accurate, and cost-effective brain tumour diagnosis to a far greater number of patients, offering hope and improving outcomes for those affected by this devastating disease.
The development represents a triumph of scientific innovation and clinical collaboration, demonstrating the power of targeted research to address critical unmet needs in healthcare. As this technology becomes more widely available, it is poised to redefine the standard of care for brain tumour patients, offering a brighter and more hopeful future. The ability to receive a definitive diagnosis within hours, rather than weeks, will undoubtedly alleviate immense suffering and empower clinicians to provide the most appropriate and timely treatment, ultimately saving lives and improving the quality of life for countless individuals. The implications extend beyond immediate patient care, offering valuable data for ongoing research and the development of novel therapeutic interventions.
